MON-199 KIDNEY TRANSPLANTATION IN MULTIPLE MYELOMA: CASE REPORTS
نویسندگان
چکیده
منابع مشابه
Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports
Kidney disease is a common complication in patients with multiple myeloma. Traditionally, patients with active multiple myeloma and end-stage renal disease have been excluded from kidney transplantation due to the risk of malignancy progression. The introduction of bortezomib-based therapy for patients with multiple myeloma and renal impairment has significantly improved survival in this popula...
متن کاملTandem Transplantation in Multiple Myeloma
The use of high-dose chemotherapy and autologous stem cell support in the past decade has changed the outlook for patients with multiple myeloma. In newly diagnosed patients, complete remission rates of 25% to 50% can be achieved, with median disease-free and overall survivals exceeding 3 and 5 years, respectively. Despite these results, autologous transplantation has not changed the ultimately...
متن کاملAllogeneic transplantation in multiple myeloma.
Allogeneic hematopoietic stem cell transplantation in multiple myeloma has been performed since the 1980th, but is still a controversial treatment modality. The aim is to cure the disease and the rational is to eradicate myeloma cells by the dual effect of high dose myeloablative treatment, and the immune reaction against the myeloma cells by the graft (graft versus myeloma =GVM). At the same t...
متن کاملMULTIPLE MYELOMA Stem cell transplantation in multiple myeloma
High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to increase survival and time to progression in multiple myeloma (IMM) compared with conventional chemotherapy. In the French IFM90-study [1], 200 patients were randomised to receive prolonged standard treatment with i.v. combination chemotherapy, or a short phase by induction treatment with the same regim...
متن کاملTandem Transplantation in Multiple Myeloma
The use of high-dose chemotherapy and autologous stem cell support in the past decade has changed the outlook for patients with multiple myeloma. In newly diagnosed patients, complete remission rates of 25% to 50% can be achieved, with median disease-free and overall survivals exceeding 3 and 5 years, respectively. Despite these results, autologous transplantation has not changed the ultimately...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International Reports
سال: 2019
ISSN: 2468-0249
DOI: 10.1016/j.ekir.2019.05.994